Senl-T7 CAR-T Cells for Treatment of Relapsed or Refractory CD7+ Lymphoma
Clinical trial NCT04928105 · UNKNOWN
Trial details
- NCT number
- NCT04928105
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
- Status
- UNKNOWN
- Phase
- Not Applicable
- Study type
- INTERVENTIONAL
- Start date
- 2021-01-27
- Primary completion
- 2023-01-31
- Enrollment
- 100
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.